Uterine sarcoma part III—Targeted therapy: The Taiwan Association of Gynecology (TAG) systematic review

Autor: Jen-Ruei Chen, Li-Te Lin, Peng-Hui Wang, Mu-Hsien Yu, Cheng-Chang Chang, Chen-Yu Huang, Yen-Mei Hsu, Fa-Kung Lee, Yu-Min Ke, Fong-Yuan Ju, Wen-Hsun Chang, Yih-Ron Lien, Chih-Ping Chen, Yen-Hou Chang, Yi Chang, Men-Luh Yen, Sen-Wen Teng, Yeou-Lih Wang, Hung Cheng Lai, Wen-Yih Wu, Kuan-Chin Wang, Song-Nan Chow, Pao-Ling Torng, Chih-Long Chang, Ruey-Jian Chen, Na-Rong Lee, Chih-Ping Tsai, Heung-Tat Ng, Yao Ching Hung, Wen-Shiung Liou, Yen-Feng Lu, Fei-Chi Chuang, Wen-Ling Lee, Tsung-Hsuan Lai, Pi-Lin Sun, Kuan-Hao Tsui, Chin-Jung Wang, Sheng-Mou Hsiao, Kok-Min Seow, Kuan-Chong Chao, Wu Chou Lin, Hsiang-Tai Chao, Ling-Yu Jiang, Huann-Cheng Horng, Jyh-Shin Chiou, Tze-Chien Chen, Chih-Yao Chen, Fu-Tsai Kung, Chii-Hou Chen, Lee-Wen Huang, Wei Min Liu, Shu-Yun Huang, Chia-Hao Liu, Chia-Hao Chan, Kuo Chang Wen, Her-Young Su, Bor-Ching Sheu, Yi-Jen Chen, Ju-Yueh Li, Hsin-Yang Li, Ming-Shyen Yen, Yiu-Tai Li, Ching-Hung Hsieh, Shing-Jyh Chang, Kuo Feng Huang, Ching-Chuang Chu, Jian-Pei Huang, Lin-Hung Wei, Chuan-Chi Shih, Jeng-Hsiu Hung, Chi-Mu Chuang, Hung-Chun Fu, Tze-Ho Chen, Lou Sun, Jah-Yao Liu, Hua-Hsi Wu, Meng Hsing Wu, Po-Hui Wang, Ming-Chao Huang, San-Nung Chen, Kuan-Hui Huang, Ching-Hui Chen, Man-Jung Hung, Wei Chun Chang, Yu Chi Wang, Ben-Shian Huang, An-Jen Chiang, Shih Tien Hsu, Wen-Chun Chang, Chien-Hsing Lu, Chiou-Chung Yuan, Kuo-Hu Chen, Hsiao-Wen Tsai, Hsu-Dong Sun, Chi-Hong Ho
Rok vydání: 2016
Předmět:
Zdroj: Taiwanese Journal of Obstetrics & Gynecology, Vol 55, Iss 5, Pp 625-634 (2016)
ISSN: 1028-4559
DOI: 10.1016/j.tjog.2016.07.001
Popis: Uterine sarcoma is a very aggressive and highly lethal disease. Even after a comprehensive staging surgery or en block cytoreduction surgery followed by multimodality therapy (often chemotherapy and/or radiation therapy), many patients relapse or present with distant metastases, and finally die of diseases. The worst outcome of uterine sarcomas is partly because of their rarity, unknown etiology, and highly divergent genetic aberration. Uterine sarcomas are often classified into four distinct subtypes, including uterine leiomyosarcoma, low-grade uterine endometrial stromal sarcoma, high-grade uterine endometrial stromal sarcoma, and undifferentiated uterine sarcoma. Currently, evidence from tumor biology found that these tumors showed alternation and/or mutation of genomes and the intracellular signal pathway. In addition, some preclinical studies showed promising results for targeting receptor tyrosine kinase signaling, phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway, various kinds of growth factor pathways, Wnt/beta-catenin signaling pathway, transforming growth factor β/bone morphogenetic protein signal pathway, aurora kinase A, MDM2 proto-oncogene, histone deacetylases, sex hormone receptors, certain types of oncoproteins, and/or loss of tumor suppressor genes. The current review is attempted to summarize the recurrent advance of targeted therapy for uterine sarcomas.
Databáze: OpenAIRE